European Patent Office Grants Patent for Sativex

The European Patent Office has granted a patent for endocannabinoid modulator Sativex with an exclusivity period until August 2023.

UK's GW Pharmaceuticals has been granted a patent by the European Patent Office, which protects the composition of its Sativex formulation. This patent has already been granted in the US.

Sativex is an endocannabinoid modulator made of two actives – THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol).

The patent, entitled ‘Cannabinoid Liquid Formulations for Mucosal Administration’, provides an exclusivity period until August 2023.

In addition to this patent, Sativex is protected by a number of other patents related to different aspects of the product.

"The grant of this patent is part of a matrix of in